SEC Form 4 · accession 0001127602-17-009668

Bioverativ Inc. · BIVV

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — EVP, Business Development

Period of report

Feb 28, 2017

Accepted (ET)

Mar 2, 2017 · 4:06 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001681689

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock^F1,F2	Feb 28, 2017	A	27,376	$0.00	A	27,633	D
Common Stock^F3	Feb 28, 2017	F	51	$43.42	D	27,582	D
Common Stock^F3	Feb 28, 2017	F	22	$49.56	D	27,560	D
Common Stock^F3	Feb 28, 2017	F	45	$47.76	D	27,515	D
Common Stock^F3	Feb 28, 2017	F	939	$43.42	D	26,576	D
Common Stock^F3	Feb 28, 2017	F	411	$49.56	D	26,165	D
Common Stock^F3	Feb 28, 2017	F	837	$47.76	D	25,328	D
Common Stock^F3	Feb 28, 2017	F	25	$43.42	D	25,303	D
Common Stock^F3	Feb 28, 2017	F	429	$43.42	D	24,874	D
Common Stock^F3	Feb 28, 2017	F	339	$49.56	D	24,535	D
Common Stock^F3	Feb 28, 2017	F	681	$47.76	D	23,854	D
Common Stock^F3	Feb 28, 2017	F	66	$43.42	D	23,788	D
Common Stock^F3	Feb 28, 2017	F	1,100	$43.42	D	22,688	D

No Table II lines on this filing.

F1Includes restricted stock units granted by Bioverativ Inc. ("Bioverativ") to the reporting person as a result of the conversion of existing Biogen Inc. ("Biogen") cash-settled performance units and market stock units held by the reporting person prior to the spin-off of Bioverativ from Biogen on February 1, 2017 ("Spin-Off"), as set forth in an employee matters agreement entered into between Bioverativ and Biogen in connection with the Spin-Off. Restricted stock units that are unvested continue to vest on the dates of the original Biogen awards.
F2Includes 257 shares acquired in a pro rata distribution by Biogen in connection with the Spin-Off.
F3Represents the number of shares forfeited by the reporting person to cover the payment of taxes incurred as a result of vesting of restricted stock units.